IRB #

STUDY00018238

Title

Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator

Uma Borate

Study Purpose

This is a clinical trial to assess the safety of ruxolitinib and venetoclax administered in combination for the treatment of patients with relapse or refractory acute myeloid leukemia (AML).

Medical Condition(s)

relapsed/refractory acute myeloid leukemia

Eligibility Criteria

Patients with relapsed or refractory acute myeloid leukemia

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

At least one month or a minimum of 12 months follow-up from the first dose of study drugs. If there is clinical benefit with treatment study drug will be provided. We will follow you for up to 5 years following your first dose of study drug.

Minors Included

No

Contact

Madison Hayes
503-494-3835
hayema@ohsu.edu

Sponsor

Uma Borate, MD

Recruitment End

02/01/2022

Compensation Provided

No


Go Back